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Abstract
Friedreich ataxia (FRDA) is a neurodegenerative disorder caused by an unstable GAA repeat
expansion mutation within intron 1 of the FXN gene. However, the origins of the GAA repeat
expansion, its unstable dynamics within different cells and tissues, and its effects on frataxin
expression are not yet completely understood. Therefore, we have chosen to generate
representative FRDA mouse models by using the human FXN GAA repeat expansion itself as the
genetically modified mutation. We have previously reported the establishment of two lines of
human FXN YAC transgenic mice that contain unstable GAA repeat expansions within the
appropriate genomic context. We now describe the generation of FRDA mouse models by
crossbreeding of both lines of human FXN YAC transgenic mice with heterozygous Fxn knockout
mice. The resultant FRDA mice that express only human-derived frataxin show comparatively
reduced levels of frataxin mRNA and protein expression, decreased aconitase activity, and
oxidative stress, leading to progressive neurodegenerative and cardiac pathological phenotypes.
Coordination deficits are present, as measured by accelerating rotarod analysis, together with a
progressive decrease in locomotor activity and increase in weight. Large vacuoles are detected
within neurons of the dorsal root ganglia (DRG), predominantly within the lumbar regions in 6-
month-old mice, but spreading to the cervical regions after 1 year of age. Secondary
demyelination of large axons is also detected within the lumbar roots of older mice. Lipofuscin
deposition is increased in both DRG neurons and cardiomyocytes, and iron deposition is detected
in cardiomyocytes after 1 year of age. These mice represent the first GAA repeat expansion-based
FRDA mouse models that exhibit progressive FRDA-like pathology and thus will be of use in
testing potential therapeutic strategies, particularly GAA repeat-based strategies.
© 2006 Elsevier Inc. All rights reserved.
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Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder that is
predominantly caused by a homozygous GAA repeat expansion mutation within intron 1 of
the FXN gene (formerly FRDA) [1]. Normal individuals have 5 to 30 GAA repeat
sequences, whereas affected individuals have from approximately 70 to more than 1000
GAA triplets [2]. The effect of the GAA expansion mutation is to reduce greatly the
expression of frataxin [3], a mitochondrial protein that interacts with succinate
dehydrogenase complex subunits [4] and acts both as an iron chaperone in iron–sulfur
clusters and heme biosynthesis [5–8] and as an iron detoxifier [9]. A direct correlation has
been identified between the size of the smaller of the two GAA repeat mutations (and hence
the level of residual frataxin expression) and the age of onset and severity of FRDA disease
phenotype [3,10–12]. Evidence suggests that the GAA repeat expansion may have its effect
by adopting an abnormal triplex structure that interferes with FXN gene transcription
[13,14], possibly by the formation of a sticky DNA complex that sequesters transcription
factors [15]. It has also been suggested that GAA repeats may produce a heterochromatin-
mediated gene silencing effect [16].
The generation of a representative mouse model of FRDA is considered important for the
further understanding of disease pathology and the testing of potential therapeutic strategies.
Thus far, strategies have been based on various gene-targeting approaches to modify the
homologous mouse Fxn gene. Initially, Fxn knockout mice were shown to be embryonic
lethal in the homozygous state [17]. Several Cre/loxP conditional knockout mice have
subsequently been generated. These have each been shown to reproduce some pathological
features of FRDA, including dysfunction of large sensory neurons, cardiodegeneration,
diabetes, deficiency of Fe–S-containing enzymes, oxidative stress, and mitochondrial iron
accumulation [18–21]. Despite these successes, conditional knockout models are by their
nature selective in the tissues that contain loss or decreased levels of frataxin and they do not
address the question of GAA repeat mutation dynamics. A different gene-targeting approach
is to introduce a GAA repeat mutation into the mouse Fxn locus. However, this GAA repeat
knock-in strategy is somewhat hampered by the fact that the Fxn intron 1 region of the
mouse does not normally contain a GAA repeat sequence. Indeed, knock-in of a 230-GAA
repeat sequence into the Fxn intron 1 has not reproduced triplet repeat instability in mice,
although it did result in decreased frataxin production [22].
We hypothesized that a human genomic FXN transgene that contained a GAA repeat
expansion at the correct intronic position would enable both GAA repeat instability and
reduced frataxin expression to be obtained within the one single model. Our previous work
demonstrated that a wild-type FXN YAC transgene could successfully rescue the embryonic
lethal phenotype of the Fxn knockout mouse [17], indicating that the YAC contained the
necessary regulatory elements for appropriate human frataxin expression in a frataxin null
mouse [23]. We have subsequently generated two lines of human FXN YAC transgenic
mice containing GAA repeat expansions derived from FRDA patient DNA that exhibit
intergenerational and somatic instability of the GAA repeat [24]. We now describe the
generation of GAA repeat expansion-based FRDA mouse models by crossbreeding of these
FXN YAC transgenic mice with heterozygous Fxn knockout mice. Offspring are produced
that express comparatively reduced levels of human-derived frataxin and rescue the
homozygous Fxn knockout embryonic lethality. We detect FRDA-like biochemical,
histopathological, and functional losses that will allow these mouse models to be used for
testing effective FRDA therapeutic strategies.
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Results
Human GAA expansion-containing FXN YAC transgenes rescue FRDA knockout
embryonic lethality
Two lines of human FXN YAC transgenic mice that contain GAA repeat expansions of
approximately 190 repeats or 190 + 90 repeats, designated YG22 and YG8, respectively,
have previously been described [24]. To determine the viability of each GAA FXN
transgene, we set up crosses between YG22 or YG8 mice (FXN+, Fxn+/+) and heterozygous
Fxn knockout mice (Fxn+/−) [17]. The FXN+, Fxn+/− offspring from these crosses were
further bred with Fxn+/− mice to generate FXN+, Fxn−/− “rescues.” Correct Mendelian ratios
of rescue mice to overall offspring number were obtained from both YG22 and YG8 crosses
(p > 0.25 in each case), indicating functional frataxin derived from both GAA repeat-
containing transgenes. The rescue mice from both lines exhibit a normal life span, with mice
surviving up to at least 2 years of age.
Decreases in frataxin mRNA and protein expression
To determine the levels of frataxin mRNA expression in YG22 and YG8 rescue and
transgenic mice we performed semiquantitative RT-PCR using primers that recognize both
human and mouse frataxin cDNA, followed by digestion with human-specific and mouse-
specific restriction enzymes. The DNA products were standardized by comparison with
mouse Hprt RT-PCR controls and were then determined as a percentage of wild-type mouse
values. The results confirmed the presence of human-only frataxin mRNA transcripts in both
YG22 and YG8 rescue mice (Fig. 1A). The levels of transgenic FXN mRNA expression
compared to endogenous mouse Fxn mRNA revealed decreases in all YG22 and YG8 rescue
mouse tissues (Fig. 1B). The greatest, and statistically significant, decreases were detected
in the cerebellum of both YG22 (62%) and YG8 (57%) rescues, together with the skeletal
muscle of YG8 rescues (57%). This contrasted with YG22 and YG8 transgenic mouse
samples, which all showed increases (101 to 145%) in overall frataxin mRNA expression,
with approximately equal contributions from transgenic and endogenous frataxin mRNA.
To determine the levels of human frataxin expression in YG22 and YG8 rescue mice we
used an anti-human recombinant mature frataxin antibody (α-hmfxn) in Western blot
analysis of several different tissue lysates. Our initial analysis of equalized unaffected
human and wild-type mouse skeletal muscle samples indicated that the α-hmfxn antibody
reacts strongly with human frataxin to give a band of 18 kDa, but reacts only weakly with
mouse frataxin to give a slightly larger band of 19 kDa (Fig. 2A). We determined the ratio of
human to mouse signal intensities to be 2.3:1. Thus, although a direct comparison between
the human frataxin levels in the YG22 and YG8 rescue mice and wild-type mouse frataxin
levels was not possible, we were able to calculate the comparative levels of human frataxin
indirectly. Analysis of our results (Fig. 2B–2D) revealed comparative frataxin levels of 67
and 86% in the cerebellum, 45 and 52% in the heart, and 23 and 23% in the skeletal muscle
of YG22 and YG8 rescue mice, respectively, when standardized to an anti-porin
mitochondrial antibody control (p < 0.01 for all, except YG8 cerebellum, which was not
significant). These frataxin expression levels were further decreased to 67 and 42% in
cerebellum, 37 and 25% in heart, and 10 and 9% in skeletal muscle of YG22 and YG8
rescue mice, respectively, when standardized to an anti-actin antibody control (p < 0.01 for
all). This suggests that there is both a decrease in the relative amount of frataxin within the
mitochondria and an overall decrease in mitochondria within the cells of these tissues,
especially within the YG8 cerebellar and heart tissues compared with the corresponding
YG22 tissues. Some confirmation of this latter point comes from our finding of variably
decreased (60–90%) levels of porin in all YG22 and YG8 cerebellum, heart, and skeletal
muscle tissues, compared with wild-type controls (data not shown). In contrast, the levels of
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frataxin in the cerebrum and brain stem from both YG22 and YG8 rescue mice are not
similarly reduced, but show increases of between 1 and 2 times the endogenous mouse
levels when standardized to porin and levels of 0.7 to 2.2 times when standardized to actin
(Figs. 2B–2D). These data suggest an increased amount of frataxin within the mitochondria
of the cerebrum and brain stem of both mice, with an approximately normal number of
mitochondria in YG22, but a decrease in YG8. The fluctuating decreased or increased levels
of frataxin protein that we determined in different rescue mouse tissues contrasts with our
finding of constant decreased frataxin mRNA levels in all rescue mouse tissues. This
discrepancy may be explained by tissue-dependent variations in posttranscriptional and
posttranslational effects on transgenic frataxin protein production.
To investigate potential antioxidant changes, comparative levels of the antioxidant enzymes,
CuZnSOD and MnSOD, were also determined from the same tissue lysates (Figs. 2B, 2E,
and 2F). CuZnSOD showed increases of up to 166% in cerebrum, brain stem, cerebellum,
and heart of both YG22 and YG8 rescue mice compared with wild-type controls and
normalized with actin, although changes were not to a significant level. However, a
significant decrease in CuZnSOD was detected in the skeletal muscle of both YG22 and
YG8 rescue mice (40 and 22%, respectively, p < 0.01 for each). MnSOD showed increases
of up to 146% in all tissues (with the exception of YG8 skeletal muscle, which was
decreased to 80%) compared with wild-type controls and normalized with porin, although
changes were not to a significant level.
Neurobehavioral deficits
The coordination ability of the YG22 and YG8 rescue mice was shown to be impaired from
the age of 3 months as determined by reduced performance on an accelerating rotarod
treadmill compared with wild-type littermate controls (p < 0.01) (Fig. 3A). However, the
degree of impairment did not extend to overt ataxia in either line of mice up to the age of 2
years. Muscle strength, assessed by a forelimb grip strength test, was decreased in YG22
rescues from 9 months of age (p < 0.01), but no significant changes were detected in the
YG8 rescues (Fig. 3B). Locomotor activity, assessed by examining the unrestricted
movement of mice in an open field, was decreased in both lines. The YG22 rescues showed
a decreased trend in locomotor activity from 6 months of age, but no statistically significant
difference was seen until 1 year (p < 0.05). YG8 rescues, on the other hand, showed a
significant decrease in locomotor activity from 6 months of age (p < 0.05) (Fig. 3C). Both
YG22 and YG8 lines demonstrated an increase in weight, with statistically significant
differences detected in YG22 rescues from 6 months of age (p < 0.01) and in YG8 rescues
from 9 months of age (p < 0.01) (Fig. 3D). One reason for the observed gain in weights may
be the decreased locomotor activity identified in the mice.
Electrophysiological analysis
Motor and sensory nerve conduction studies were performed on the sciatic and caudal
nerves of 9- to 14-month-old YG22 rescue and wild-type control mice and 20-month-old
YG8 rescue and wild-type control mice. Decreases in both the sensory action potential and
the sensory conduction velocity of the older YG8 rescue mice were detected (Fig. 4),
although not to statistical significance. However, no sensory nerve conduction changes were
detected in the younger YG22 rescues, and no motor nerve conduction changes were
detected in either line of mice (data not shown). Taken together, these findings suggest a
mild, progressive peripheral sensory neuropathy, which is consistent with an FRDA
phenotype.
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Histological abnormalities in the dorsal root ganglia (DRG) and heart
To detect possible neuronal histopathology in the YG22 and YG8 rescue mice, we examined
sections of brain, spinal cord, and DRG from eight YG22 rescues, six YG8 rescues, and
three wild-type mice. By performing H&E staining and anti-calbindin immunohistology, we
did not identify any of the cerebellar Purkinje cell abnormalities or granule cell losses that
have previously been reported for frataxin conditional knockout mice [20]. Neither did we
detect any abnormalities in the brain or spinal cord regions of either line of mice. However,
we did identify pathological changes in the DRG. Prominent giant vacuoles were identified
in the large sensory neuronal cell bodies of the DRG in both YG8 and YG22 rescue mice but
not in wild-type controls (Fig. 5A). The vacuoles are round, single or multiple, and appear to
be empty. We also detected peripheral margination of the nucleus in many large neuronal
cell bodies, with or without vacuoles, suggestive of the process of central chromatolysis.
These findings indicate specific degeneration of cells that also are a primary site of
pathology in FRDA patients. Interestingly, the occurrence of DRG vacuoles shows a
progressive position-dependent profile, which is similar in both lines of mice. Between the
ages of 6 months to 1 year, vacuoles are detected only in the DRG of the lumbar region, but
after 1 year of age, vacuoles also become apparent within DRG of the cervical region.
Approximately 60% of the lumbar DRG sections from YG22 rescues and 70% of the lumbar
DRG sections from YG8 rescues have cells containing vacuoles, with one to seven cells
affected in each DRG section. In contrast, only 16% of the cervical DRG sections have
vacuoles, and the vacuoles are detected in only one cell per DRG section. This profile
resembles the distal-to-proximal “dying-back” phenomenon of neurodegeneration that is
observed in FRDA patients.
To determine potential hypertrophic cardiomyopathy, the heart weight/body weight ratio
was determined and the heart examined for histopathology by H&E, trichrome Masson, and
Perl’s staining. No increase in heart weight to body weight ratio was identified and no
myofibril disarray or fibrosis was observed to suggest cardiomyopathy (data not shown).
However, Perl’s staining identified iron deposition within the heart, but only from the oldest
(14–18 months) YG22 rescue mice studied (Fig. 5B). In these cases, Perl’s staining of the
cardiomyocytes was prominent but sparse, consistent with similar findings in FRDA
patients.
Ultrastructure pathology
Ultrastructure examination of lumbar DRG from 20-month-old YG8 rescue mice by electron
microscopy confirmed the presence of large vacuoles within the large neuronal cell bodies
(Fig. 6A), as previously detected by light microscopy. Chromatolysis was also confirmed by
the finding of dispersion of the rough endoplasmic reticulum ribosomes, leaving regions of
the cell devoid of any cytoplasmic organelles (Fig. 6B). Lipofuscin deposition, which
represents a lysosomal protein polymer arising from iron-catalyzed oxidation, was
pronounced in DRG neurons (Fig. 6C). Other changes within the lumbar DRG included the
finding of swelling and secondary demyelination of large axons (Figs. 6D and 6E). These
pathological changes are all in keeping with oxidative stress and mitochondrial dysfunction
of degenerating large DRG neurons, which are then attempting to regenerate by activation of
protein synthesis. Ultrastructure examination of the heart identified patches of lipofuscin
deposition and lysosomes, together with an accumulation of dispersed free glycogen,
disrupting the regular arrays of mitochondria within the cardiomyocytes (Fig. 6F).
Lipofuscin deposition is a recognized feature within FRDA cardiomyocytes and dispersed
free glycogen accumulation leading to myofibril distortion has been found in other forms of
hypertrophic cardiomyopathy [25].
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Decreased aconitase activity and mitochondrial respiratory chain function
Previous studies of FRDA patient and mouse model tissues have demonstrated impaired
activity of the iron–sulfur cluster (ISC)-containing aconitase enzyme and mitochondrial
respiratory chain (MRC) complexes I, II, and III, but not the non-ISC-containing MRC
complex IV [18,26]. Examination of heart tissue samples from 6-month-old YG8 rescue
mice detected a decrease in aconitase activity to approximately 66% of wild-type mouse
levels (p < 0.05) (Fig. 7). Decreases in MRC complex I and II/III activity were also detected
(79 and 75% of controls, respectively), although not to significant levels. In contrast,
isolated MRC complex II and MRC complex IV activities showed no change. These data are
in general agreement with the previous reports of FRDA patient and mouse model samples.
However, the isolated MRC complex II activity was not decreased in the YG8 rescue mice,
as has previously been described in conditional knockout mouse models [18,20]. Therefore,
it is possible that the level of frataxin reduction in these samples is only just sufficient to
induce changes in the most sensitive enzyme, aconitase. The impaired aconitase activity
may be due to either reduced ISC formation or oxidative damage.
Oxidative stress
To detect potential oxidative stress in our FRDA models, we determined the levels of
oxidized proteins and malondialdehyde (MDA; a marker of lipoperoxides) in YG22 and
YG8 rescue mouse cerebrum, cerebellum, heart, and skeletal muscle tissues compared with
wild-type controls. Oxidized proteins were increased in all samples from both YG22 and
YG8 rescue mice (Fig. 8A). The most prominent significant increases were detected in the
cerebrum and cerebellum of both lines (p < 0.01), with lesser, but still significant, increases
also detected in the heart and skeletal muscle of both YG8 (p < 0.01) and YG22 (p < 0.05)
mice. The finding of increased oxidized proteins in the YG22 cerebrum is somewhat at odds
with our previous finding of an increased level of frataxin protein in this tissue, suggesting
reduced functional efficiency of the transgenic human frataxin protein. Increased lipid
peroxidation, as determined by MDA levels, was also detected in cerebrum and heart
samples from YG22 rescue mice, but only the heart showed a statistically significant
increase (p < 0.05) (Fig. 8B).
Discussion
Although the exact mechanisms that cause FRDA are still under investigation, several
specific features of FRDA molecular pathology are now well established. Thus, the majority
of FRDA patients are homozygous for GAA repeat expansion mutations within intron 1 of
the FXN gene, leading to decreased levels of frataxin, subsequent oxidative stress, iron
deposition, and ultimately neurodegeneration, primarily in the large sensory neurons of the
DRG, and hypertrophic cardiomyopathy. We have been able to recapitulate many such
features of FRDA disease in the mouse by establishing two lines of model mice that express
frataxin only from GAA repeat expansion-containing FXN transgenes.
We have previously shown that the GAA repeat somatic instability pattern in our YG22 and
YG8 transgenic mice closely resembles the GAA repeat dynamics in FRDA patients [24].
Our initial interpretation of the Western blot data from this study, which showed a more
intense signal from the human frataxin compared to the mouse frataxin, led us to speculate
on likely overexpression of human frataxin in YG22 or YG8 knockout rescue mice [24].
However, we have now demonstrated that both YG22 and YG8 rescue mice express
comparatively decreased levels of human frataxin mRNA in all tissues and decreased levels
of human frataxin protein in at least some tissues compared with endogenous mouse levels.
Overall the YG8 rescue mice demonstrate slightly less frataxin mRNA and protein
expression, combined with marginally higher amounts of protein oxidation, compared with
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the YG22 mice. Therefore, it is possible that the additional 90 GAA repeats in the YG8 line
are responsible for producing a slightly more severe phenotype. Previous GAA expansion
mutation knock-in studies have shown that mice expressing 25–36% endogenous mouse
frataxin levels do not show an obvious pathological phenotype [22], although a clear
microarray gene expression phenotype has been determined [27]. These mouse frataxin
levels are similar to the human frataxin levels that we have determined in our heart samples.
However, due to its slightly different amino acid composition, human frataxin may not
function at 100% of endogenous mouse frataxin efficiency. Therefore, the levels of frataxin
that we see here (67 and 42% in cerebellum, 37 and 25% in heart, and 10 and 9% in skeletal
muscle of YG22 and YG8 rescue mice, respectively) may in fact represent an even more
“functional” decrease, resulting in the pathological phenotype that we describe.
Age-related somatic increases in GAA repeats have previously been detected in the
cerebrum, brain stem, and cerebellum of both YG22 and YG8 transgenic mice, but no such
increases were detected in the heart or skeletal muscle [24]. Therefore, the pattern of
frataxin expression in our YG22 and YG8 rescue mice (highest in cerebrum and brain stem,
lowest in skeletal muscle) is not likely to be entirely due to somatic increases in GAA repeat
expansions. A similar pattern of “high brain and low skeletal muscle” frataxin expression
has been reported in lines of human FXN BAC transgenic mice that contain normal-sized
GAA repeats [28]. Thus, unknown tissue-specific regulatory factors would appear to be
acting on human FXN transgenes within the context of the mouse. As yet there are
insufficient data available on human tissue samples to determine if a similar differential
pattern of frataxin expression is present in FRDA and thus how representative our mouse
models are in this regard.
That being said, the differentially reduced levels of frataxin in our mouse models are
sufficient to induce a mild FRDA-like pathological phenotype. Impaired aconitase activity,
oxidative stress, and functional deficits are apparent, although not severe, and neuronal
histopathology and iron deposition within the heart are later progressive effects. This
phenotype is indicative of the early effects of FRDA pathology that precede overt ataxia and
the later development of hypertrophic cardiomyopathy. Indeed, these mild mouse models
can be considered representative of the less severe, later onset cases of FRDA. The 190 and
190 + 90 GAA repeat expansion mutation sizes within our mouse models are also in keeping
with the cases of later onset FRDA that have smaller GAA allele sizes of fewer than 200
repeats [29–33].
The vacuoles identified in the DRG of our mouse models appear similar to those in the “Cb”
neuron-specific frataxin conditional knockout model reported by Simon et al. [20].
However, an additional finding within our models is the progression of vacuolar pathology
from affected distal lumbar regions at only 6 months of age to more proximal cervical
regions at 13–15 months. This resembles the dying-back phenomenon of neurodegeneration
that is observed in FRDA patients. Although, to our knowledge, DRG vacuoles have not
been described in FRDA patients, loss of large sensory DRG cell bodies is a hallmark of the
disease. Thus, it is likely that we are identifying a milder or earlier effect in our mouse
models, before the DRG neurons degenerate and are lost completely. The identification of
lipofuscin deposition, chromatolysis, and swelling and demyelination of axons in the DRG
can be explained by cells that are suffering from chronic oxidative damage. In this sense, our
FRDA mouse models are similar to the mouse model of ataxia with vitamin E deficiency,
which shows lipofuscin deposition in DRG of mice over 1 year of age, indicating chronic
oxidative stress [34]. Although frataxin conditional knockout mouse models have
reproduced many other features of FRDA pathology, there is currently some debate
concerning oxidative stress status. Studies of neuronal and cardiac conditional knockout
models indicate no, or insignificant, oxidative stress [35,36], whereas pancreatic and hepatic
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conditional knockout models demonstrate distinct oxidative stress [19,21]. Our own models
demonstrate an obvious, but not severe, degree of oxidative stress. This may be due to the
fact that our models have residual frataxin in all tissues, which may also be the case with the
pancreatic and hepatic knockout models, but not the neuronal and cardiac knockout models,
which have complete frataxin loss in specific tissues. Our mice also have a mitochondrial
respiratory chain that shows only a slight overall functional deficit and, therefore, continues
to produce damaging free radicals. The greater loss of aconitase activity than MRC complex
activity deficits suggests that aconitase impairment is a prominent early feature, even in mild
cases of FRDA. The increases that we found in CuZnSOD and MnSOD are generally
consistent with a reaction to oxidative stress in our FRDA mouse model tissues. However,
where there is the greatest decrease in frataxin (i.e., skeletal muscle) we actually see a
decrease in both CuZnSOD and MnSOD. This indicates a different susceptibility or
handling of this tissue to mild oxidative stress. The identification of iron deposition in the
hearts of only our older mice confirms the later onset aspect of this pathology, as previously
described for cardiac frataxin conditional knockout mouse mutants [18].
Understanding that FRDA is caused by an unstable GAA repeat sequence, leading to
decreased levels of frataxin, has given rise to novel ideas for frataxin-increasing therapies.
We believe that we have generated a GAA-repeat-based mouse model of FRDA that would
be suitable for the investigation of many different therapeutic strategies. These include the
possible use of iron chelators and antioxidants, targeted preferentially to the mitochondria
[37,38], as well as novel drugs aimed at up-regulation of frataxin expression, such as hemin,
butyric acid, and cisplatin [39,40]. However, the fact that our FRDA mouse models have
been generated by the introduction of a GAA repeat expansion mutation also makes them
amenable to novel therapeutic strategies aimed at interacting with and modifying the GAA
repeat expansion itself.
Materials and methods
Production and genotyping of genetically modified mice
GAA repeat expansion-containing YG8 and YG22 transgenic mice [24] were first crossed
with heterozygous Fxn knockout mice [17] to produce mice containing both the transgene
and the knockout allele. A second cross with heterozygous Fxn knockout mice then
produced viable FRDA model mice containing the human FXN transgene on an Fxn null
background. Genotyping of GAA repeats and Fxn allele status was performed as previously
described [24].
mRNA and protein expression analysis
mRNA was isolated and RT-PCR amplified for 25 cycles using human/mouse frataxin exon
3/4 primers FRT1 and RRTII, followed by digestion with mouse-specific BstXI and human-
specific AflIII restriction enzymes as previously described [23]. Mouse Hprt RT-PCR was
also carried out for 25 cycles using the primers and conditions described by Puccio et al.
[18]. DNA products were resolved in 3% agarose gels and UV images were analyzed by
UN-SCAN-IT (Silk Scientific Corp.) densitometry.
Frataxin Western blot analysis was carried out using a recombinant anti-mature frataxin
antibody (G. Isaya, Mayo Clinic) as previously described [23]. Other immunodetection was
carried on the same Western blots using antibodies against actin (Sigma), porin (Cambridge
Bioscience), MnSOD (Abcam), and CuZnSOD (Abcam). Densitometry was carried out
using UN-SCAN-IT software (Silk Scientific Corp.).
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Functional studies
Rotarod analysis was performed using a Ugo-Basille 7650 accelerating rotarod treadmill
apparatus. Mutant and control littermate mice ages 3, 6, 9, and 12 months (n=5–10) were
placed on the rod and four trials were performed with the speed of the rotation gradually
increasing from 4 to 40 rpm over a period of approximately 3–5 min. A period of 10 min
rest was given between each trial. The time taken for each mouse to fall from the rod was
recorded. Grip strength was assessed by holding mice by the base of the tail, while their
forepaws gripped onto a horizontal bar that was attached to a tension spring. The mice were
gently pulled backward until they let go of the bar and the distance pulled in millimeters was
recorded. Locomotor activity was assessed by placing the mice in a gridded open-field
Perspex box and the number of gridded squares entered by the mouse over a period of 20 s
was recorded.
Electrophysiology
Electrophysiological recordings were carried out on anesthetized 20-month-old YG8 rescue
mice, 9- to 14-month-old YG22 rescue mice, and wild-type controls. Motor nerve
conduction was investigated by placing electrodes in the hind-paw muscle and stimulating
the sciatic nerve. Measurements of amplitude, distal latency, and proximal latency were
taken, and the motor conduction velocity was then determined. Sensory nerve conduction
was investigated by placing electrodes at two positions in the tail skin and stimulating the
caudal nerve. Measurements of the sensory action potential were taken, and the sensory
conduction velocity was then determined.
Histology
For histological preparations, terminally anesthetized mice were fixed by intracardial
perfusion with 4% paraformaldehyde in phosphate-buffered saline (PBS). The fixed mouse
tissues were dissected, embedded in paraffin wax, and sectioned by standard methods.
Sections were deparaffinized with Histoclear (National Diagnostics) and slides were stained
with hematoxylin and eosin or trichrome Masson stains. Perl’s technique was used to detect
ferric iron as previously described [17].
Electron microscopy
Mice of 20 months of age were perfused via a cannula in the heart with 1% glutaraldehyde
and 1% paraformaldehyde plus 1% dextran, all in 0.1 M PIPES buffer. Tissues were
dissected out, fixed for several hours in the same solution, and then postfixed overnight in
1% osmium tetroxide +1.5% potassium ferricyanide and 3% sodium iodate. Tissues were
then dehydrated through increasing concentrations of ethanol and embedded in Durcupan
via 1,2-epoxy propane. Thin sections for light microscopy were stained with thionin and
acridine orange and ultrathin sections for electron microscopy were contrasted with uranyl
acetate and lead citrate.
Biochemical measurements
Dissected mouse heart tissues were snap-frozen in liquid nitrogen. Mitochondrial respiratory
chain and aconitase activities were determined as previously described [26].
Oxidative stress
Protein lysates were prepared according to Campuzano et al. [3]. For each assay, 10 μg of
protein was used and the concentration was determined by using the BCA Protein Assay
Reagent Kit (Pierce). Proteins were then modified by the use of the OxyBlot Protein
Oxidation Detection Kit (Chemicon International). Duplicate samples were used for each
assay and controls of unmodified samples were also included. After the assay was
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performed according to the manufacturer’s instructions, each sample was diluted to 100 μl
in 1× Laemmli buffer [41], with 2-mercaptoethanol and no added glycerol. Samples were
then applied to a slot-blot apparatus and washed with the same buffer, followed by
electroblot transfer buffer. The filters were air-dried and treated with the antibody provided
in the kit and subsequently visualized on X-OMAT X-ray film. Densitometry was performed
using UN-SCAN-IT software (Silk Scientific Corp.) and the final values were calculated as
ratios to the protein concentration used per assay.
TBARS (thiobarbituric acid-reactive substances) assay for MDA
Using a modification of the method described by Ledwozyw et al. [42], brain and heart
tissues from wild-type and mutant mice were homogenized to 20% (w/v) in Dulbecco’s
PBS. Samples were then centrifuged at 2000g for 10 min and supernatants were collected.
Each supernatant (0.1 ml) was mixed with 20% (w/v) trichloroacetic acid in 0.6 M HCl and
left at room temperature for 15 min. This was then mixed with thiobarbituric acid (TBA;
prepared by dissolving 0.5 g of TBA in 6 ml of 1 M NaOH and then adding 69 ml of water).
The mixture was then heated to 100°C for 30 min, cooled to room temperature for 10 min,
and then extracted with 0.8 ml of n-butanol. Samples were vortexed and then centrifuged at
1500g for 10 min. The upper organic phase was collected and the absorbance of each sample
was determined at 532 nm vs n-butanol. The concentration of MDA (which forms an adduct
with TBA) was determined from a standard curve, obtained from using different
concentrations of MDA (Aldrich). The protein concentration of each tissue homogenate
supernatant was determined by the BCA Protein Assay (Pierce) and the final value of MDA
in each tissue was presented as nmol/mg of protein used.
Statistical analysis
Mendelian ratios were determined using χ2 analysis, rotarod analysis was carried out using
ANOVA with repeated measures, and all other functional, mRNA, Western blot, oxyblot,
TBARS, and enzyme activities were analyzed using the Student t test.
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Fig. 1.
mRNA expression analysis. (A) A representative RT-PCR image showing restriction-
digested human frataxin products (112 and 29 bp) and mouse frataxin products (75 and 64
bp), together with mouse Hprt controls. mRNA samples were isolated from tissues of wild-
type, YG22 rescue, YG8 rescue, YG22 transgenic, and YG8 transgenic mice (lanes 1,
cerebrum; 2, brain stem; 3, cerebellum; 4, heart; 5, skeletal muscle). (B) Levels of frataxin
mRNA expression as a percentage value of wild-type mouse expression. Values were
generated by determining the means of six different RT-PCR experiments, each normalized
to Hprt. Error bars indicate SEM. *p<0.05, **p<0.01.
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Fig. 2.
Frataxin and antioxidant enzyme expression levels in YG22 and YG8 rescue mice. (A)
Western blot showing comparative levels of frataxin relative to actin in skeletal muscle
samples from human (H), wild-type mouse (M), and YG22 transgenic mouse (TG). (B)
Western blot of YG22 and YG8 rescue mouse tissue lysates (lanes 1, cerebrum; 2, brain
stem; 3, cerebellum; 4, heart; 5, skeletal muscle) hybridized with antibodies against frataxin,
actin, porin, MnSOD, and CuZnSOD. The very low levels of YG8 skeletal muscle frataxin,
which appear to be negative in this image, were revealed upon longer exposure. (C, D)
Levels of transgenic human frataxin expression as a percentage value of endogenous wild-
type mouse frataxin expression, (C) relative to porin controls or (D) relative to actin controls
(n=5–8). Tissues 1–5 are as described for (B). (E) Levels of CuZnSOD in rescue mice as a
percentage value of wild-type mouse expression, normalized to actin (n=3–7). Tissues 1–5
are as described for (B). (F) Levels of MnSOD in rescue mice as a percentage value of wild-
type mouse expression, normalized to porin (n=3–6). Tissues 1–5 are as described for (B).
Error bars indicate SEM. *p<0.05, **p<0.01.
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Fig. 3.
Functional studies of 3-, 6-, 9-, and 12-month-old YG22 and YG8 rescue mice, compared
with wild-type controls. (A) Rotarod analysis of YG22 and YG8 rescue mice compared with
wild-type littermate controls shows a coordination deficit in both rescue mice from 3 months
of age (n=10 and 9, respectively). However, a direct comparison between YG22 and YG8
experiments is not possible due to the use of different rotarod acceleration rate settings
carried out at different periods of time. (B) Grip strength analysis shows a weakness in
YG22 rescues only from 9 months of age (n=6–10). (C) Locomotor analysis identifies a
progressive decrease in the mobility of both rescue mice (n=6–8 and 7–13, respectively). (D)
Weight increases are detected in both rescue mice (n=6–16). Error bars indicate SEM.
*p<0.05, **p<0.01.
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Fig. 4.
Sensory nerve conduction studies of 20-month-old YG8 rescue mice and wild-type controls
showing a decrease in sensory conduction velocity (SCV) and sensory action potential
(SAP), although not to significance (n=2).
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Fig. 5.
Neuronal and cardiac histopathology. (A) H&E-stained section of lumbar DRG from a
representative YG22 rescue mouse over 1 year of age, showing two neurons containing
large vacuoles. Original magnification 400×. (B) Perl’s staining of a heart section from a
representative YG22 rescue mouse over 1 year of age, showing characteristic blue staining
indicating iron deposition. Original magnification 600×.
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Fig. 6.
(A–E) Electron micrographs of lumbar DRG from 20-month-old YG8 rescue mice showing
examples of: (A) giant vacuoles, (B) chromatolysis, and (C) lipofuscin deposits within the
large neuronal cell bodies. Also detected within the lumbar DRG are instances of: (D)
complete demyelination of a large axon with its associated Schwann cell and (E) large
axonal swelling with reduced myelination. (F) Electron micrograph of cardiac muscle from a
20-month-old YG8 rescue mouse showing lipofuscin deposition and lysosomes disrupting
an ordered array of mitochondria. Scale bars represent 10 μm.
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Fig. 7.
Mitochondrial respiratory chain and aconitase activities in heart tissue from 6-month-old
YG8 rescue mutant and control mice. (A) The specific activities of aconitase (Acon) and
citrate synthase (CS). CS activities were divided by 10 (n=6). (B) The mitochondrial
respiratory chain (MRC) activities expressed as a ratio with citrate synthase; MRC I, NADH
coenzyme Q1 reductase (NQ1R); MRC II/III, succinate cytochrome c reductase (SCcR);
MRC II, succinate coenzyme Q2 reductase (SQ2R); and MRC IV, cytochrome oxidase
(COX). COX/CS ratio was multiplied by a factor of 10 (n=4). Activities are expressed as
means ± SEM. *p=0.03.
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Fig. 8.
Oxidative stress. (A) Oxyblot analysis detects protein oxidation in cerebrum, cerebellum,
heart, and skeletal muscle tissues of 6- to 9-month old YG22 and YG8 rescue mice,
compared with wild-type controls, measured in arbitrary units (a.u.) of densitometry (n =8–
12). Error bars indicate SEM. *p < 0.05, **p < 0.01. (B) TBARS analysis shows levels of
MDA (nmol/mg of protein) as a marker of lipoperoxidation in YG22 cerebrum and heart
tissue compared with wild-type controls (n=6). Error bars indicate SEM. *p<0.05.
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